T Cell Modification and Use Thereof
AssigneeAdaptimmune Limited
InventorsGarth Hamilton, Jonathan Silk, Claire Gueguen
Life of this patent
Estimating the term…
Loading patent…
AssigneeAdaptimmune Limited
InventorsGarth Hamilton, Jonathan Silk, Claire Gueguen
Estimating the term…
This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen. The modified T cells may comprise a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule, a second nucleotide sequence encoding the antigen receptor; an inducible promoter operably linked to the first nucleotide sequence and a constitutive promoter operably linked to the second nucleotide. Nucleic acid constructs and vectors are provided, as well as T cells comprising such constructs and vectors and therapeutic methods and uses thereof.
A T cell comprising a constitutively expressed antigen receptor and an inducibly expressed IL-7 molecule, wherein the antigen receptor is a chimeric antigen receptor (CAR) that binds to a tumor antigen, or is a T cell receptor (TCR) that binds to an MHC-displayed peptide fragment of the tumor antigen.
A method of producing a population of modified T cells, the method comprising introducing into a population of T cells a nucleic acid construct comprising
Dependencies are inferred from the claim text.